

# Michael Slade

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1481702/publications.pdf>

Version: 2024-02-01

38  
papers

654  
citations

687220

13  
h-index

580701

25  
g-index

38  
all docs

38  
docs citations

38  
times ranked

1452  
citing authors

#	ARTICLE	IF	CITATIONS
1	Severe Cytokine-Release Syndrome after T Cellâ€“Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Antiâ€“IL-6 Therapy Is Safe and Well Tolerated. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1851-1860.	2.0	135
2	Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation. <i>Transplant Infectious Disease</i> , 2017, 19, e12629.	0.7	75
3	Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. <i>Haematologica</i> , 2016, 101, e465-e468.	1.7	54
4	Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 318-324.	2.0	54
5	Rapid detection of donor cell free DNA in lung transplant recipients with rejections using donor-recipient HLA mismatch. <i>Human Immunology</i> , 2017, 78, 342-349.	1.2	49
6	Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1736-1743.	2.0	44
7	T Cellâ€“Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 648-653.	2.0	38
8	Post-transplant high-dose cyclophosphamide after HLA-matched vs haploidentical hematopoietic cell transplantation for AML. <i>Bone Marrow Transplantation</i> , 2016, 51, 1561-1564.	1.3	34
9	Cardiomyopathy in patients after posttransplant cyclophosphamideâ€“based hematopoietic cell transplantation. <i>Cancer</i> , 2017, 123, 1800-1809.	2.0	27
10	Halfway there: the past, present and future of haploidentical transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 1-6.	1.3	26
11	Donor-lymphocyte infusion following haploidentical hematopoietic cell transplantation with peripheral blood stem cell grafts and PTCy. <i>Bone Marrow Transplantation</i> , 2017, 52, 1623-1628.	1.3	21
12	Propensity Score Analysis of Conditioning Intensity in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2047-2055.	2.0	18
13	HLA epitope mismatch in haploidentical transplantation is associated with decreased relapse and delayed engraftment. <i>Blood Advances</i> , 2018, 2, 3590-3601.	2.5	16
14	Untreated donor specific antibodies against HLA are associated with poor outcomes in peripheral blood haploidentical hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 898-901.	1.3	13
15	CD123 bi-specific antibodies in development in AML: What do we know so far?. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101219.	0.7	12
16	The Predicted Indirectly Recognizable HLA Epitopes (PIRCHE) Score for HLA Class I Graft-versus-Host Disparity Is Associated with Increased Acute Graft-versus-Host Disease in Haploidentical Transplantation with Post-Transplantation Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 123-131.	2.0	9
17	Remobilization of hematopoietic stem cells in healthy donors for allogeneic transplantation. <i>Transfusion</i> , 2016, 56, 2331-2335.	0.8	7
18	Cytomegalovirus Viremia and Relapse after Haploidentical Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S320.	2.0	6

#	ARTICLE	IF	CITATIONS
19	Single institution experience with G-CSF mobilized T-cell replete haploidentical hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 769-771.	1.3	3
20	Donor-Derived Smoldering Multiple Myeloma following a Hematopoietic Cell Transplantation for AML. <i>Case Reports in Hematology</i> , 2017, 2017, 1-3.	0.3	3
21	Cutaneous graft-versus-host disease incidence is similar in haploidentical and matched unrelated hematopoietic transplant recipients: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1654-1658.	0.6	3
22	Can planned CD34+ stem cell boost prevent poor graft function after peripheral blood haploidentical hematopoietic transplantation?. <i>Leukemia and Lymphoma</i> , 2021, 62, 749-751.	0.6	3
23	Infectious Complications after Peripheral Blood (PB) Haploidentical Hematopoietic Cell Transplantation (haplo-HCT). <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S176-S177.	2.0	1
24	Use of Myeloablative or Reduced Intensity Conditioning with Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia and MDS is Associated with Similar Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S279.	2.0	1
25	The effect of donor type on outcomes in adults with acute myeloid leukemia after reduced-intensity hematopoietic peripheral blood cell transplant – a retrospective study. <i>Transplant International</i> , 2020, 33, 1089-1098.	0.8	1
26	Impact of Donor Age and Relationship on Outcomes of Peripheral Blood Haploidentical Hematopoietic Cell Transplantation. <i>Blood</i> , 2021, 138, 2924-2924.	0.6	1
27	The impact of diabetes mellitus and other comorbidities on hematopoietic stem cell collection and hematologic recovery post-transplantation. <i>Leukemia and Lymphoma</i> , 2017, 58, 241-243.	0.6	0
28	A Small Cemetery. <i>Journal of Clinical Oncology</i> , 2021, 39, 2313-2313.	0.8	0
29	Cytomegalovirus (CMV) disease in peripheral blood (PB) allogeneic hematopoietic cell transplant (HCT) with post-transplant cyclophosphamide (PT-Cy).. <i>Journal of Clinical Oncology</i> , 2016, 34, e18538-e18538.	0.8	0
30	Impact of KIR-ligand mismatch on outcomes after peripheral blood haploidentical hematopoietic cell transplantation.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7051-7051.	0.8	0
31	Post-Transplant Outcomes in AML Patients ≥ 60 Years of Age Beyond CR1. <i>Blood</i> , 2016, 128, 4696-4696.	0.6	0
32	Haploidentical Transplant with Peripheral Blood Hematopoietic Cell Grafts in Older Adults with AML or MDS. <i>Blood</i> , 2016, 128, 4658-4658.	0.6	0
33	Haploidentical Hematopoietic Cell Transplantation Using G-CSF Mobilized T-Cell Replete Grafts for Acute Leukemia and MDS. <i>Blood</i> , 2016, 128, 2278-2278.	0.6	0
34	Absolute Lymphocyte Count Recovery Predicts Post Transplant Outcomes in Peripheral Blood Haploidentical Transplantation. <i>Blood</i> , 2016, 128, 4698-4698.	0.6	0
35	HLA Class II Epitope Mismatch Influences Relapse and Engraftment in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation. <i>Blood</i> , 2018, 132, 4634-4634.	0.6	0
36	The Impact of Tocilizumab Treatment for Cytokine Release Syndrome on the Incidence of Blood Stream Infections after Peripheral Blood Haploidentical Hematopoietic Cell Transplantation. <i>Blood</i> , 2021, 138, 1800-1800.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Comparison of Deep Whole Exome Versus Targeted Gene Sequencing for Assessment of Persistent Molecular Disease in Acute Myeloid Leukemia Samples. <i>Blood</i> , 2020, 136, 6-7.	0.6	0
38	The impact of tocilizumab treatment for cytokine release syndrome on the incidence of early blood stream infections after peripheral blood haploidentical hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 0, , 1-7.	0.6	0